Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967940 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
A Phase 3 study of HIV Infections and HIV, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
- 15
- Study locations
NCT01967940 is a Phase 3 study of HIV Infections and HIV that has completed, run by Gilead Sciences. The registered enrollment target is 55 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (88% lower). The trial reports 15 study locations across 4 states.
The verdict
NCT01967940, a Phase 3 study of HIV Infections and HIV, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of tenofovir alafenamide (TAF) versus placebo, each administered with the existing, failing antiretroviral (ARV) regimen. There are 2 parts to this study: Part 1 and Part 2. Part 1 consists of 2 cohorts, starting with a sentinel cohort, in which participants will be enrolled to receive open-label TAF in addition to their current failing ARV regimen. This cohort will then be followed by a randomized, double-blind, cohort to compare the addition of TAF or placebo in HIV-1 positive adults who are failing their current ARV regimen. In Part 2, all participants who complete Part 1 of the study will discontinue their failing ARV regimen and TAF or placebo for a 14-day washout period. Following the washout period, all participants who received TAF in Part 1 and have a \> 0.5 log10 decline in HIV-1 RNA will receive elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single-tablet regimen (STR) plus atazanavir (ATV) once daily for 48 weeks. Participants who received TAF who have a ≤ 0.5 log10 decline in HIV-1 RNA will be discontinued from the study and will not be eligible to continue into Part 2 of the study. All participants who received placebo in Part 1 will be eligible to participate in Part 2 regardless of their viral load change. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TAF
- DRUG ATV
- DRUG E/C/F/TAF
- DRUG Current failing ARV regimen
Study Locations (15)
Other
- Salvador B Gautier Hospital - Infectious Diseases Department - Santo Domingo
- Instituto Dominicano de Estudio Virologicos - IDEV - Santo Domingo
- Regional state budget health agency Krasnoyarsk Regional Center for Prevention and Control of AIDS - Krasnoyarsk
- Center For Prevention and Treatment of AIDS and Infectious Diseases, Saint Petersburg - Saint Petersburg
- The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) - Bangkok
- Ramathibodi Hospital, Mahidol University - Bangkok
- Siriraj Hospital Department of Preventive and Social Medicine, Faculty of Medicine - Bangkok
- Chiang Mai University - Chiang Mai
- Khon Kaen University - Khon Kaen
- Joint Clinical Research Centre - Kampala
Florida
- Midway Immunology and Research center - Ft. Pierce
- Triple O Research Institute, P.A. - West Palm Beach
- Rowan Tree Medical, P.A. - Wilton Manors
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Pennsylvania
- Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2013-10-25 |
| Est. Completion | 2017-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01967940
The ClinicalTrials.gov registry entry for NCT01967940 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (88% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01967940 reports 15 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01967940 about?
NCT01967940 is a clinical study titled "Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults". The primary objective of this study is to evaluate the efficacy of tenofovir alafenamide (TAF) versus placebo, each administered with the existing, failing antiretroviral (ARV) regimen. There are 2 parts to this study: Part 1 and Part 2. Part 1 consists of 2 cohorts, starting with a sentinel cohort...
What is the current status of trial NCT01967940?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2013-10-25. Estimated completion is 2017-07-31.
What conditions does trial NCT01967940 study?
This clinical trial studies the following conditions: HIV Infections, HIV, Acquired Immunodeficiency Syndrome.
What interventions are being tested in trial NCT01967940?
The interventions under investigation include: Placebo (DRUG), TAF (DRUG), ATV (DRUG), E/C/F/TAF (DRUG), Current failing ARV regimen (DRUG).
Who is sponsoring clinical trial NCT01967940?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01967940 being conducted?
This trial has 15 study locations across Florida, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.